|Day Low/High||221.79 / 228.23|
|52 Wk Low/High||177.05 / 264.97|
The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...
RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.
Stocks secure robust gains after the latest labor market snapshot breezes past expectations.
These sectors offer value as the S&P 500 trades at 19x earnings.
The two Big Pharma giants are looking for new ways to drive growth through anti-cancer treatments.
The sector seems to be rebounding after tumbling by more than 40%.
The bifurcation can be seen just by looking at Apple's recent results.
That may be the best way to get through the notorious month of August.
Facebook (FB) smashed earnings expectations--again. Shares are hitting record highs in the pre-market.
Stocks remain very unconcerned about rates, despite the odds of a fall increase slightly rising.
The market continues to trade lower as we late morning, with Tobira Therapeutics serving as the "disaster du jour" in the small-cap biotech space. This stock is trading down some 60% after its midstage compound targeting non-alcoholic steatohepatiti...
A look at who will be up and who will down this earnings season.
You have to be impressed by the breadth of XNCR's pipeline and significant partnerships with major players.
Traders and investors should either stand aside or start probing the short side.
Large biotech stocks are still at their cheapest valuations since 2011.
A fresh rally leg could be on the way if AMGN can remain above the $152 area in the near term.
Keep cash on hand and be ready for oportunities as they arise.
But there is no guarantee that it will fully play out.
It is hard to see much growth in the market overall, until earnings growth returns.
The S&P 500 is testing the neckline of a head-and-shoulders pattern.
The cream of the biotech crop seems to have found a floor after a rough set of earnings.